CN1187085C - 促红细胞生成素用于生产脑局部缺血药物的应用 - Google Patents

促红细胞生成素用于生产脑局部缺血药物的应用 Download PDF

Info

Publication number
CN1187085C
CN1187085C CNB998160474A CN99816047A CN1187085C CN 1187085 C CN1187085 C CN 1187085C CN B998160474 A CNB998160474 A CN B998160474A CN 99816047 A CN99816047 A CN 99816047A CN 1187085 C CN1187085 C CN 1187085C
Authority
CN
China
Prior art keywords
erythropoietin
cerebral ischemia
stroke
patients
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998160474A
Other languages
English (en)
Chinese (zh)
Other versions
CN1335776A (zh
Inventor
亨内罗尔·埃伦里希
克里斯多夫·格莱特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7891015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1187085(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CN1335776A publication Critical patent/CN1335776A/zh
Application granted granted Critical
Publication of CN1187085C publication Critical patent/CN1187085C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
CNB998160474A 1998-12-14 1999-12-13 促红细胞生成素用于生产脑局部缺血药物的应用 Expired - Fee Related CN1187085C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19857609.9 1998-12-14
DE19857609A DE19857609A1 (de) 1998-12-14 1998-12-14 Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen

Publications (2)

Publication Number Publication Date
CN1335776A CN1335776A (zh) 2002-02-13
CN1187085C true CN1187085C (zh) 2005-02-02

Family

ID=7891015

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998160474A Expired - Fee Related CN1187085C (zh) 1998-12-14 1999-12-13 促红细胞生成素用于生产脑局部缺血药物的应用

Country Status (26)

Country Link
US (1) US7514072B1 (enExample)
EP (1) EP1140139B2 (enExample)
JP (2) JP4750947B2 (enExample)
KR (1) KR100774827B1 (enExample)
CN (1) CN1187085C (enExample)
AT (1) ATE253932T1 (enExample)
AU (1) AU766216C (enExample)
BG (1) BG65417B1 (enExample)
BR (1) BR9916197A (enExample)
CA (1) CA2353553C (enExample)
DE (2) DE19857609A1 (enExample)
DK (1) DK1140139T4 (enExample)
ES (1) ES2211218T5 (enExample)
HK (1) HK1042655B (enExample)
HU (1) HUP0104709A3 (enExample)
ID (1) ID29107A (enExample)
IL (2) IL143579A0 (enExample)
MX (1) MXPA01005971A (enExample)
NO (1) NO330079B1 (enExample)
NZ (1) NZ541591A (enExample)
PL (1) PL202483B1 (enExample)
PT (1) PT1140139E (enExample)
RO (1) RO121409B1 (enExample)
RU (1) RU2242991C2 (enExample)
WO (1) WO2000035475A2 (enExample)
ZA (1) ZA200104626B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
NZ533098A (en) * 1999-04-13 2006-04-28 Kenneth S Modulation of excitable tissue function by peripherally administered erythropoietin at high doses
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7410941B1 (en) 1999-04-13 2008-08-12 The Kenneth S. Warren Institute, Inc. Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
US7078376B1 (en) 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
DE10043457A1 (de) * 2000-09-04 2002-03-28 Hannelore Ehrenreich Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
PA8536201A1 (es) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
JP3993560B2 (ja) * 2001-08-30 2007-10-17 ステム セル セラピューティクス インコーポレイテッド 神経幹細胞の分化およびその治療用途
AU2002325711C1 (en) 2001-09-14 2008-05-29 Stem Cell Therapeutics Inc. Prolactin induced increase in neutral stem cell numbers and therapeutical use thereof
DE10219545A1 (de) * 2002-04-26 2003-11-06 Lang Florian Regulation der Apoptose
JP2005534650A (ja) * 2002-06-11 2005-11-17 ザ バーナム インスティテュート エリスロポイエチンおよびインスリン様増殖因子の神経保護的相乗作用
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US20040209812A1 (en) * 2003-03-27 2004-10-21 Renzi Michael J. Use of erythropoietin in stroke recovery
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
US20070111932A1 (en) * 2003-07-31 2007-05-17 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
KR20070008519A (ko) 2003-09-29 2007-01-17 워렌 파마슈티칼즈 인코포레이티드 패혈증 및 유착 형성의 치료 및 예방용 조직 보호성사이토카인
EP1675573B2 (en) 2003-10-23 2012-06-13 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
CA2556266A1 (en) * 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh), and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
US9988427B2 (en) 2005-05-13 2018-06-05 Charite Universitaetsmedizen-Berlin Erythropoietin variants
EP1736481A1 (en) 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
EP2279727A3 (en) * 2005-09-15 2011-10-05 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
KR20080074108A (ko) 2005-09-27 2008-08-12 스템 셀 테라퓨틱스 코포레이션 프로락틴에 의해 조절되는 올리고덴드로사이트 전구체 세포증식
AU2007229301B2 (en) 2006-03-17 2013-08-01 Stem Cell Therapeutics Corp. Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents
TW200815026A (en) * 2006-06-07 2008-04-01 Univ Tokushima Treatment of ischemic diseases using erythropoietin
JP4879349B2 (ja) * 2007-07-31 2012-02-22 大塚製薬株式会社 アリピプラゾール懸濁液及び凍結乾燥製剤の製造方法
RU2446834C2 (ru) * 2010-06-15 2012-04-10 Елена Александровна Лебедева Способ лечения пострадавших с сочетанной черепно-мозговой травмой
US9956265B2 (en) 2011-04-26 2018-05-01 Ajou University Industry-Academic Cooperation Foundation Composition for aiding surgical procedures for treating ischemic vascular diseases
RU2495688C1 (ru) * 2012-03-28 2013-10-20 Государственное бюджетное учреждение здравоохранения Центр организации специализированной медицинской помощи "Челябинский государственный институт лазерной хирургии" Способ лечения ишемии головного мозга в эксперименте
US9610444B2 (en) 2013-03-15 2017-04-04 Pacesetter, Inc. Erythropoeitin production by electrical stimulation
KR20190052855A (ko) 2017-11-09 2019-05-17 대한제당 주식회사 페길레이션된 에리스로포이에틴을 포함하는 허혈성 뇌질환 치료용 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US5013718A (en) * 1986-11-21 1991-05-07 Amgen, Inc. Method for treating iron overload using EPO
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
EP0747485B1 (en) 1989-11-06 1998-12-02 Cell Genesys, Inc. Production of proteins using homologous recombination
EP1482053A3 (en) 1989-12-22 2007-10-17 Laboratoires Serono SA Eukaryotic host cell line in which an endogenous gene has been activated, and uses thereof
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
JP3537151B2 (ja) 1991-12-26 2004-06-14 中外製薬株式会社 脳機能障害による疾患の予防・治療薬
RU2068268C1 (ru) * 1992-03-19 1996-10-27 Учебно-научный центр Медицинского центра при Правительстве РФ Способ профилактики церебро-васкулярных заболеваний
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
BR9406490A (pt) 1993-04-29 1996-03-05 Abbott Lab Análogo de eritropoietina humana,DNA de filamento duplo,vetor de expressão célula de mamiferos em cultura composição farmaceutica segundo e terceiro análogo de eritropoietina humana e processos para fabricar um segundo análogo de eritropoietina e para usar um segundo análogo
IL192290A0 (en) 1993-08-17 2008-12-29 Kirin Amgen Inc Erythropoietin analogs
SE520730C2 (sv) 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
NZ533098A (en) 1999-04-13 2006-04-28 Kenneth S Modulation of excitable tissue function by peripherally administered erythropoietin at high doses
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs

Also Published As

Publication number Publication date
DK1140139T3 (da) 2004-03-15
KR100774827B1 (ko) 2007-11-07
ZA200104626B (en) 2002-09-06
CA2353553A1 (en) 2000-06-22
RU2242991C2 (ru) 2004-12-27
NZ541591A (en) 2007-08-31
KR20010082346A (ko) 2001-08-29
EP1140139B2 (de) 2009-03-18
IL143579A (en) 2007-10-31
AU766216C (en) 2004-11-11
AU2283100A (en) 2000-07-03
ATE253932T1 (de) 2003-11-15
BG105575A (en) 2002-01-31
CN1335776A (zh) 2002-02-13
CA2353553C (en) 2011-05-17
EP1140139B1 (de) 2003-11-12
RO121409B1 (ro) 2007-05-30
JP2002532432A (ja) 2002-10-02
ES2211218T5 (es) 2009-06-03
NO20012896D0 (no) 2001-06-12
BR9916197A (pt) 2001-09-04
PT1140139E (pt) 2004-04-30
HUP0104709A2 (hu) 2002-04-29
MXPA01005971A (es) 2002-03-27
WO2000035475A3 (de) 2000-10-19
ID29107A (id) 2001-07-26
HK1042655B (zh) 2005-09-23
IL143579A0 (en) 2002-04-21
EP1140139B9 (de) 2004-03-31
US7514072B1 (en) 2009-04-07
WO2000035475A2 (de) 2000-06-22
ES2211218T3 (es) 2004-07-01
PL202483B1 (pl) 2009-06-30
NO20012896L (no) 2001-08-14
EP1140139A2 (de) 2001-10-10
HUP0104709A3 (en) 2002-05-28
DK1140139T4 (da) 2009-06-08
NO330079B1 (no) 2011-02-14
JP2011079860A (ja) 2011-04-21
DE59907752D1 (de) 2003-12-18
JP4750947B2 (ja) 2011-08-17
AU766216B2 (en) 2003-10-09
HK1042655A1 (en) 2002-08-23
PL349335A1 (en) 2002-07-15
BG65417B1 (bg) 2008-07-31
DE19857609A1 (de) 2000-06-15

Similar Documents

Publication Publication Date Title
CN1187085C (zh) 促红细胞生成素用于生产脑局部缺血药物的应用
Aho et al. The effect of intravenously administered dexmedetomidine on perioperative hemodynamics and isoflurane requirements in patients undergoing abdominal hysterectomy
EP0638309A1 (en) Substances inhibiting proteic adp ribosilation suitable to prevent the diabetes mellitus complications
Eidemak et al. Intravenous versus subcutaneous administration of recombinant human erythropoietin in patients on haemodialysis and CAPD
Faris Use of recombinant human erythropoietin in the perioperative period of orthopedic surgery
CN1434719A (zh) 具有动员活性的制剂
JPH03190823A (ja) エリスロポエチン皮下又は筋肉投与剤
DE69315840T2 (de) Verfahren zur verabreichung einer lösung von granulozyten-kolonie-stimulierendem faktor
US20060166885A1 (en) Treatment and prevention of decubitus
RU2808256C1 (ru) Способ персонифицированной генной терапии при угрозе ишемического инсульта головного мозга
Toleubayev et al. Regenerative properties of recombinant human erythropoietin in the Wound Healing
CN109865127B (zh) 经修饰的胸腺素β4在治疗糖尿病周围神经病变方面的用途
Boran et al. Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients
DE60225576T2 (de) Verfahren zur unterdrückung der bildung von seromen mit faktor xiii
Evers Iron‐poly (sorbitol‐gluconic acid) complex and iron‐dextran in the treatment of severe iron deficiency anaemia
DE69734069T2 (de) Humanes wachstumshormon als hilfe gegen unterkühlung
EP4340865A1 (en) Use of erythropoietin (epo) or erythropoiesis-stimulating agent (esa) to treat osteomyelitis, bone infection, and bone inflammation
CA2561222A1 (en) Combination dosing regimen for erythropoietin

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050202

Termination date: 20131213